Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29416323 | 1.00 | NPC1 (0.33) | NPC1MEN1KMT2ACA2CHKA | |
| SCHEMBL1660866 | 0.88 | — | — | |
| SCHEMBL16513728 | 0.84 | NPC1 (0.33) | NPC1MEN1KMT2ACA2CHKA | |
| SCHEMBL1660333 | 0.84 | CA2 (0.39) | NPC1MEN1KMT2ACA2CHKA | |
| SCHEMBL1661082 | 0.82 | CA2 (0.38) | NPC1MEN1KMT2ACA2CHKA | |
| SCHEMBL1660874 | 0.82 | NPC1 (0.35) | NPC1MEN1KMT2A | |
| SCHEMBL278866 | 0.82 | CA2 (0.37) | NPC1CA2CHKALMNARAB9A | |
| SCHEMBL16532258 | 0.80 | CA2 (0.36) | NPC1MEN1KMT2ACA2CHKA | |
| SCHEMBL16513889 | 0.79 | NPC1 (0.30) | NPC1 | |
| SCHEMBL22065025 | 0.79 | NPC1 (0.30) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720036-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | 16380026 Canada Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720037-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | 16380026 Canada Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| US-12577456-B2 | Light-emitting element, light-emitting device, electronic device, lighting device, and novel organic compound | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2026-03-17 | — | — | US | disclosed |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250098516-A1 | Organometallic Complex, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2025-03-20 | — | — | US | disclosed |
| EP-4520329-A2 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4509512-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-12167675-B2 | Organometallic complex, light-emitting element, light-emitting device, electronic device, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2024-12-10 | — | — | US | disclosed |
| WO-2024243692-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2024-12-05 | — | — | WO | disclosed |
| US-20120035178-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-09 | — | — | US | disclosed |
| WO-2011045353-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (GB) | 2011-04-21 | — | — | WO | disclosed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100331348-A1 | TROPANE DERIVATIVES USEFUL AS PESTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331348-A1 | TROPANE DERIVATIVES USEFUL AS PESTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | NPC1 896/4885MEN1 3838/4885KMT2A 2891/4885 |
| US-20120035178-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | NPC1 896/4885MEN1 3838/4885KMT2A 2891/4885 |
| US-12167675-B2 | Organometallic complex, light-emitting element, light-emitting device, electronic device, and lighting device | LAGE3, NR2E3, IK | NPC1 4192/4885MEN1 797/4885KMT2A 997/4885 |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | NPC1 2892/4885MEN1 2219/4885KMT2A 2821/4885 |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | NPC1 896/4885MEN1 3838/4885KMT2A 2891/4885 |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | NPC1 3297/4885MEN1 3206/4885KMT2A 3326/4885 |
| US-12577456-B2 | Light-emitting element, light-emitting device, electronic device, lighting device, and novel organic compound | SUN2, LEF1, CTNND1 | NPC1 3204/4885MEN1 893/4885KMT2A 2087/4885 |
| US-20100331348-A1 | TROPANE DERIVATIVES USEFUL AS PESTICIDES | DDT, ACHE, TPM3 | NPC1 2473/4885MEN1 2560/4885KMT2A 4054/4885 |
| US-20250098516-A1 | Organometallic Complex, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device | LAGE3, NR2E3, IK | NPC1 4192/4885MEN1 797/4885KMT2A 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.